Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EBT Margin data on record, last reported at 126.36% in Q4 2025.

  • For Q4 2025, EBT Margin fell 4489.0% year-over-year to 126.36%; the TTM value through Dec 2025 reached 126.5%, down 2562.0%, while the annual FY2025 figure was 126.5%, 2562.0% down from the prior year.
  • EBT Margin reached 126.36% in Q4 2025 per MRVI's latest filing, down from 108.45% in the prior quarter.
  • Across five years, EBT Margin topped out at 885.05% in Q4 2023 and bottomed at 249.39% in Q3 2024.
  • Average EBT Margin over 5 years is 22.04%, with a median of 12.56% recorded in 2023.
  • Peak YoY movement for EBT Margin: soared 83822bps in 2023, then plummeted -96651bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 63.34% in 2021, then fell by -26bps to 46.83% in 2022, then soared by 1790bps to 885.05% in 2023, then tumbled by -109bps to 81.46% in 2024, then plummeted by -55bps to 126.36% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 126.36% in Q4 2025, 108.45% in Q3 2025, and 156.39% in Q2 2025.